JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

07 May 2025 16:01:25 By Nasdaq GlobeNewswire

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

23 Apr 2025 09:45:10 By NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

22 Apr 2025 16:02:52 By NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

04 Apr 2025 09:45:28 By NetDania Notify

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

01 Apr 2025 16:01:16 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

26 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

24 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

19 Mar 2025 16:01:56 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

12 Mar 2025 08:30:49 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

05 Mar 2025 16:01:06 By Nasdaq GlobeNewswire

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

04 Mar 2025 16:01:50 By Nasdaq GlobeNewswire

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

23 Jan 2025 08:30:42 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 Nov 2024 16:01:12 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

04 Nov 2024 07:00:53 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

25 Oct 2024 08:30:35 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

03 Oct 2024 08:30:23 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

09 Sep 2024 08:30:35 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 08:15:03 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

12 Aug 2024 16:01:35 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

06 Aug 2024 16:01:38 By Nasdaq GlobeNewswire